Yesterday, Aug. 26, 2015, 121 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $95.86 to $14,679,317.76.

Highlighted Stocks Traded by Insiders:

Kemet (KEM) - FREE Research Report

Borruso Joseph Vincent, who is Director at Kemet, bought 5,000 shares at $1.63 on Aug. 26, 2015. Following this transaction, the Director owned 67,867 shares meaning that the stake was boosted by 7.95% with the 5,000-share transaction.

The shares most recently traded at $1.70, up $0.07, or 3.93% since the insider transaction. Historical insider transactions for Kemet go as follows:

  • 4-Week # shares bought: 32,000
  • 12-Week # shares bought: 33,000
  • 24-Week # shares bought: 33,000

The average volume for Kemet has been 311,000 shares per day over the past 30 days. Kemet has a market cap of $71.9 million and is part of the technology sector and electronics industry. Shares are down 62.86% year-to-date as of the close of trading on Wednesday.

KEMET Corporation, together with its subsidiaries, manufactures and sells various capacitors under the KEMET brand worldwide. The company operates through two segments, Film and Electrolytic Business Group and Solid Capacitors Business Group. Currently, there are no analysts who rate Kemet a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on KEM - FREE

TheStreet Quant Ratings

rates Kemet as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, weak operating cash flow and poor profit margins. Get the full

Kemet Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Investment Technology Group (ITG) - FREE Research Report

Selway James P. III, who is Managing Director at Investment Technology Group, bought 1,250 shares at $15.70 on Aug. 26, 2015. Following this transaction, the Managing Director owned 84,076 shares meaning that the stake was boosted by 1.51% with the 1,250-share transaction.

The shares most recently traded at $16.43, up $0.73, or 4.44% since the insider transaction. Historical insider transactions for Investment Technology Group go as follows:

  • 4-Week # shares bought: 8,250
  • 4-Week # shares sold: 3,200
  • 12-Week # shares bought: 8,250
  • 12-Week # shares sold: 3,200
  • 24-Week # shares bought: 8,250
  • 24-Week # shares sold: 47,800

The average volume for Investment Technology Group has been 475,200 shares per day over the past 30 days. Investment Technology Group has a market cap of $530.6 million and is part of the financial sector and financial services industry. Shares are down 23.63% year-to-date as of the close of trading on Wednesday.

Investment Technology Group, Inc. operates as an independent execution and research broker in the United States, Canada, Europe, and the Asia Pacific regions. The stock currently has a dividend yield of 1.79%. The company has a P/E ratio of 18.2. Currently, there are no analysts who rate Investment Technology Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITG - FREE

TheStreet Quant Ratings

rates Investment Technology Group as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Investment Technology Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Sorrento Therapeutics (SRNE) - FREE Research Report

Ji Henry, who is President and CEO at Sorrento Therapeutics, bought 500 shares at $0.95 on Aug. 26, 2015. Following this transaction, the President and CEO owned 500 shares meaning that the stake was boosted by 100% with the 500-share transaction.

The shares most recently traded at $13.51, up $12.56, or 92.99% since the insider transaction. Historical insider transactions for Sorrento Therapeutics go as follows:

  • 4-Week # shares bought: 45,853
  • 4-Week # shares sold: 20,814
  • 12-Week # shares bought: 45,853
  • 12-Week # shares sold: 20,814
  • 24-Week # shares bought: 45,853
  • 24-Week # shares sold: 20,814

The average volume for Sorrento Therapeutics has been 828,700 shares per day over the past 30 days. Sorrento Therapeutics has a market cap of $440.3 million and is part of the health care sector and drugs industry. Shares are up 23.83% year-to-date as of the close of trading on Wednesday.

Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. Currently, there are 3 analysts who rate Sorrento Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SRNE - FREE

TheStreet Quant Ratings

rates Sorrento Therapeutics as a

sell

. Among the areas we feel are negative, one of the most important has been generally deteriorating net income. Get the full

Sorrento Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.